Recent scrutiny of Medicare Advantage plans has revealed significant concerns regarding the practices of insurers in coding patient diagnoses for reimbursement. According to a report from MedPAC in March, a health plan can increase its payment when it submits data indicating a patient has diabetes without complications, which leads to an additional $1,284. When further coding for vascular disease is included, the payment can swell by an additional $3,620, culminating in a total of $11,630 for the insurer. Alarmingly, these financial gains persist even when the patient is not actually treated for the reported conditions.
This issue highlights the way Medicare Advantage incentivizes insurers to maximize the number of diagnosis codes they report, potentially leading to inflated claims. For example, Dr. Keating from Boston has raised concerns regarding the home health assessment of a patient referred to as Mrs. G. UnitedHealth’s assessment classified Mrs. G. with several severe conditions, including chronic pain, morbid obesity, and Type 2 diabetes with complications such as cataracts and a type of nerve damage known as polyneuropathy.
However, upon Dr. Keating’s evaluation, he found a starkly different health status for Mrs. G. He diagnosed her with a relatively common spinal issue but noted that it did not involve pain. While Mrs. G. was indeed obese, it was not to a morbid degree. Furthermore, she did not exhibit signs of cataracts or polyneuropathy, and although her test results indicated she was in the pre-diabetic range, Dr. Keating concluded that she did not have diabetes.
In response to these allegations, UnitedHealth stated that it could not provide direct feedback on Dr. Keating’s specific claims. However, they clarified that diagnoses made during in-home visits are generally not used to secure payments, suggesting that coding practices are more complex than they may appear.
This situation underscores the ongoing debate over transparency and accountability in the Medicare Advantage system, raising questions about patient care quality versus financial incentives for insurance companies.
